Top Story

Optimization of ocular surface requires newer treatment options

October 31, 2014

The ocular surface and tear film can no longer be ignored, nor should they be. We have long been aware of the problems of chronic dry eye and the damage that can occur to the ocular surface. Complications can range from chronic irritation and blurry vision to infections and corneal melts. In addition, with the growing number of refractive procedures and premium IOL surgeries, it is becoming increasingly obvious how important the tear film is to vision and, therefore, how paramount it is to treat dysfunctional tear syndrome in order to obtain excellent visual outcomes. In the past, treating dry eye and tear film abnormalities has been frustrating for both the patient and physician with limited options and minimal success. However, there are innovative treatments on the horizon to address these abnormalities.

The teaching has been to separate dry eye syndrome into aqueous deficiency and evaporative tear syndrome. Evaporative tear syndrome could further be subdivided into goblet cell deficiency (as seen in conjunctival scarring), blepharitis/meibomian gland dysfunction (MGD) and lid function abnormalities (such as lagophthalmos and incomplete or partial blink). MGD makes up the majority of evaporative tear syndrome cases. The standard treatments for MGD, such as warm compresses, lid hygiene, topical and oral antibiotics, and topical anti-inflammatory agents, have been well established and are beyond the scope of this article. Now the debate has begun over whether any or all of the “procedural treatments,” such as intense pulsed light therapy, LipiFlow and meibomian gland probing, should be incorporated into the treatment regimen. I will make the argument for adopting LipiFlow into your practice.

Worth Building

Question your allocation to deal with recent stock market volatility

October 30, 2014
The summer stock market doldrums have morphed into a high octane volatile zig-zag. So I ask you – what is new? Haven’t we been here before? The trouble is…

Nicox finalizes acquisition of Aciex Therapeutics

October 30, 2014
Nicox has announced the completion of its acquisition of Aciex Therapeutics, according to a press release.In July,
figure Meeting News Coverage

Double vision main indication for therapy in half of patients with Graves' orbitopathy

October 30, 2014
CORONADO, Calif. — The main indication for therapy was double vision in around half of patients with moderate to severe Graves’ orbitopathy, according to…
More News Headlines »
Case Report

Intravitreal Polypoidal Choroidal Vasculopathy in Radiation Retinopathy

Ophthalmic Surgery, Lasers and Imaging Retina
Online Advanced Release, October 29, 2014
A 30-year-old woman diagnosed with choroidal melanoma and treated with plaque radiation and transpupillary…
More »

In Focus: Advances in AMD - Clinical Case: Long-term Management of Established Age-related Macular Degeneration

This activity is supported by an educational grant from Genentech, Inc.

Long-term management of wet age-related macular degeneration can be challenging, as medications and dosing schedules…
More »
Meeting News Coverage Video

Light adjustable lens allows precise refractive results

October 30, 2014
CHICAGO – At the American Academy of Ophthalmology, James Lehmann, MD, discusses his clinical study results…
More »